Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation.
By Yiqing Yan, Wei Jiang, Thibaud Spinetti, Aubry Tardivel, Rosa Castillo, C. Bourquin, Greta Guarda, Zhigang Tian, J. Tschopp, Rongbin Zhou. Immunity, 2013
711 citations recorded by the source corpus.
Subfields: Biochemistry, Molecular Biology, Nutrition and Dietetics
View Paper: https://www.semanticscholar.org/paper/6995c8b991a6efff8c084daed281dbe1f81932a1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. (2014, background): “[63] Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al.”
- Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms (2018, neutral): “The anti-inflammatory effects of omega-3 fatty acids seems to be mediated by binding to the G-protein–coupled receptor 120 and inhibition of NLRP3 inflammasome activity (53,54).”
- NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. (2018, background): “For example, βhydroxybutyrate, a ketone metabolite, produced during starvation or low carbohydrate prevalence, acts as an inhibitor of NLRP3(142) and omega-3 fatty acids were also shown to act as negative regulators of the NLRP3 inflammasome.(143,144) The topic of metabolic regulation of the inflamm”
- Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. (2015, neutral): “Cell Preparation and Stimulation Bone-marrow macrophages were isolated and cultured as described (Yan et al., 2013).”
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders (2017, background): “More important, we provide evidence showing that directly targeting NLRP3 itself by CY-09 could inhibit NLRP3 inflammasome activation in vivo and had remarkable therapeutic effects on the mouse models of NLRP3-driven diseases, such as T2D and CAPS. reSuLtS cY-09 specifically blocks nLrP3 activation ”